HomeABUS • NASDAQ
add
Arbutus Biopharma Corp
Nakaraang pagsara
$3.29
Sakop ng araw
$3.16 - $3.25
Sakop ng taon
$2.21 - $4.72
Market cap
600.69M USD
Average na Volume
824.53K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | 1.34M | -71.25% |
Gastos sa pagpapatakbo | 4.54M | -22.34% |
Net na kita | -19.72M | 1.92% |
Net profit margin | -1.47K | -241.18% |
Kita sa bawat share | -0.14 | 15.57% |
EBITDA | -17.14M | 18.34% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 127.79M | -4.76% |
Kabuuang asset | 140.44M | -11.47% |
Kabuuang sagutin | 33.55M | -14.64% |
Kabuuang equity | 106.89M | — |
Natitirang share | 189.49M | — |
Presyo para makapag-book | 5.87 | — |
Return on assets | -29.07% | — |
Return on capital | -35.87% | — |
Cash Flow
Net change in cash
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -19.72M | 1.92% |
Cash mula sa mga operasyon | -20.74M | 4.81% |
Cash mula sa pag-invest | -11.99M | -214.93% |
Cash mula sa financing | 1.78M | 5.59% |
Net change in cash | -30.94M | -220.11% |
Malayang cash flow | -10.88M | 21.66% |
Tungkol
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia
Itinatag
2007
Headquarters
Website
Mga Empleyado
73
